SG Americas Securities LLC Sells 48,284 Shares of Janux Therapeutics, Inc. $JANX

SG Americas Securities LLC lessened its stake in Janux Therapeutics, Inc. (NASDAQ:JANX) by 60.5% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 31,533 shares of the company’s stock after selling 48,284 shares during the quarter. SG Americas Securities LLC’s holdings in Janux Therapeutics were worth $438,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds also recently bought and sold shares of the company. Nano Cap New Millennium Growth Fund L P purchased a new stake in Janux Therapeutics during the 4th quarter valued at about $34,000. Caitong International Asset Management Co. Ltd purchased a new position in Janux Therapeutics in the fourth quarter worth about $51,000. Osaic Holdings Inc. lifted its stake in shares of Janux Therapeutics by 704.6% in the second quarter. Osaic Holdings Inc. now owns 3,468 shares of the company’s stock worth $80,000 after buying an additional 3,037 shares in the last quarter. Tower Research Capital LLC TRC lifted its stake in shares of Janux Therapeutics by 175.5% in the second quarter. Tower Research Capital LLC TRC now owns 3,928 shares of the company’s stock worth $91,000 after buying an additional 2,502 shares in the last quarter. Finally, Los Angeles Capital Management LLC purchased a new stake in shares of Janux Therapeutics during the fourth quarter valued at approximately $137,000. Institutional investors own 75.39% of the company’s stock.

Insider Buying and Selling

In other news, insider Janeen Noel Doyle sold 4,059 shares of the stock in a transaction on Tuesday, June 2nd. The stock was sold at an average price of $14.03, for a total transaction of $56,947.77. Following the transaction, the insider directly owned 75,941 shares of the company’s stock, valued at $1,065,452.23. This represents a 5.07% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, VP Maria Dobek sold 2,038 shares of the firm’s stock in a transaction on Monday, May 11th. The stock was sold at an average price of $14.17, for a total value of $28,878.46. Following the completion of the transaction, the vice president owned 32,270 shares in the company, valued at approximately $457,265.90. This trade represents a 5.94% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders own 7.90% of the company’s stock.

Janux Therapeutics Stock Up 3.2%

Shares of JANX stock opened at $16.66 on Thursday. The company has a 50 day moving average price of $14.41 and a 200-day moving average price of $14.16. Janux Therapeutics, Inc. has a 52 week low of $12.12 and a 52 week high of $35.34. The firm has a market capitalization of $1.02 billion, a PE ratio of -9.05 and a beta of 2.52.

Janux Therapeutics (NASDAQ:JANX) last released its quarterly earnings data on Thursday, May 7th. The company reported ($0.39) earnings per share for the quarter, beating the consensus estimate of ($0.52) by $0.13. The company had revenue of $3.73 million for the quarter, compared to analysts’ expectations of $4.36 million. Analysts anticipate that Janux Therapeutics, Inc. will post -1.7 earnings per share for the current year.

Wall Street Analyst Weigh In

Several brokerages recently weighed in on JANX. Wall Street Zen raised shares of Janux Therapeutics from a “sell” rating to a “hold” rating in a research report on Sunday, April 5th. Truist Financial reaffirmed a “buy” rating and issued a $26.00 price objective (down from $80.00) on shares of Janux Therapeutics in a research report on Thursday, June 25th. Barclays downgraded Janux Therapeutics from an “overweight” rating to an “underweight” rating and cut their target price for the company from $29.00 to $14.00 in a research note on Monday, April 20th. Weiss Ratings raised Janux Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a report on Wednesday, April 22nd. Finally, UBS Group cut Janux Therapeutics from a “buy” rating to a “neutral” rating and decreased their price target for the stock from $57.00 to $15.00 in a research note on Wednesday, April 15th. Ten research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $40.15.

Janux Therapeutics Profile

Janux Therapeutics is a clinical-stage biotechnology company focused on developing next-generation intratumoral immuno-oncology therapies that harness the body’s innate and adaptive immune systems. The company designs and synthesizes proprietary Toll-like receptor (TLR) agonists to reprogram the tumor microenvironment. Janux is publicly traded on the Nasdaq under the symbol JANX.

Its lead programs include JTX-8064, a fully synthetic TLR4 agonist engineered for optimal stability and potency, and JTX-4014, a TLR1/2 agonist formulated for direct intratumoral administration.